Orphazyme reports USD 90m deficit for 2021

Danish biotech firm Orphazyme, which has now been sold to Kempharm in the US, has finally released its 2021 financial report, detailing a USD 90m loss on the bottom line.

Photo: Orphazyme/PR

At the end of 2022, Orphazyme expects to have DKK 30m (USD 4.3m) in the bank, its financial report for 2021 states.

The 2021 report was postponed as the company went through an in-court restructuring process which followed a downward spiral of bad news for the company. In May, the firm and all of its assets, including candidate arimoclomol, were sold to Kempharm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs